Advertisement

Topics

EU PRIME status for Mereo’s brittle bone drug

06:05 EST 14 Nov 2017 | PharmaTimes

London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA).

Original Article: EU PRIME status for Mereo’s brittle bone drug

NEXT ARTICLE

More From BioPortfolio on "EU PRIME status for Mereo’s brittle bone drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...